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Purpose/Objective: GBM is most common primary brain tumor and 
represents an important challenge for clinicians. These neoplasms are 
resistant to radio-chemotherapy. This might be explained by the fact 
that interactions between tumor and microenvironment are involved 
in tumor radioresistance through angiogenesis, hypoxia and 
immunosuppression, or an intrinsic radioresistence of cancer stem 
cells. A molecular analysis in tumor samples or peripheral blood of 
basal activation of different signaling pathways potentially involved in 
radioresistance could be of clinical interest. Phosphatidyl-inositol 3-
kinase/protein kinase B (Akt) pathways serve to block apoptosis, 
keeping cells alive in very toxic environments such as chemotherapy 
and ionizing radiation. Polycomb group (PcG) proteins mediate gene 
silencing through histone post-translational modifications. PcG 
function is crucial for neural stem cell self-renewal. Recent evidence 
indicates that PcG genes are also required for cancer stem cell (CSC) 
propagation in neural tumors. In this study we evaluated the different 
genetic profile of Akt and EZH2 and clinical response to treatment in 
patient affected by GBM.  
Materials and Methods: Our plan is to analyze fifty patients with GBM 
treated with Radio-chemiotherapy (RT-CT) with temozolamede. Time 
to progression (TTP) after surgery or biopsy and overall survival (OS) 
will be used as clinical end-points to be correlated with 
polymorphisms of Akt and EZH2. DNA is extracted by proteinase K 
digestion. SNP genotyping was performed with the ABI PRISM 7900HT 
Sequence Detection System using primers and probes designed with 
Methyl Express software (v. 1.0). DNA samples (1-20 ng) from cancer 
tissue were amplified l multiplex Real-Time PCR. In addition, by 
quantifying themin a 25- fluorescent signals of the VIC and FAM 
probes, which specifically annealed to the two allelic sequences, the 
SDS software (v. 2.1) determined the allelic content of each sample. 
For the Quantitative Methyl Specific PCR, the Bisulfite treatment of 
DNA was performed using the Methyl SEQr Bisulfit system according to 
manufacturer’s protocol. Following bisulfite treatment, the converted 
DNA was amplified using primers designed for the altered sequences. 
Results: preliminary data is available for ninenteen patients for 
polymorphisms of Akt after a follow-up of three – thirty-six months. 
The Akt1*3 wild-type genotype was detected in 12/19 of samples and 
the heterozygous genotype was found in 7/19. We also evaluated 
Akt1*4 polymorphisms, and the only 2 patients that showed mutant 
genotype had the longest survival time. The same analysis will be 
performed in 42 peripheral blood in pts underwent to the same 
treatment for GBM, findings will be available for the ESTRO meeting in 
May.  
Conclusions: This study is currently ongoing, we actively accruing new 
cases and we are waiting for the data of peripheral blood. This 
preliminary analysis appears to indicate allelic discrimination of SNP’s 
is a senstive and reproducible method. The screening of cell line 
genotypes may add to the prognostic value of histopathology samples.  
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Purpose/Objective: Evaluation of 5-year treatment outcomes in high-
grade (grade III-IV) brain glioma patients administered conformal 
radio-(chemoradio)therapy. 
Materials and Methods: The study included 261 patients 22-74 years 
of age with Karnofsky perfomance scale of ≥ 50%. Fifty-four of them 
had pathological diagnoses of grade III anaplastic astrocytoma (AA), 17 
- grade III anaplastic oligoastrocytoma or grade III anaplastic 
oligodendroglioma (AO/AOD), and 190 - grade IV glioblastoma (GBM). 
In 2005 - 2010, 114 of them received a course of postoperative 
conformal radiotherapy at a single target dose of 1.8-2 Gy up to total 
target doses (TTD) of 54-60 Gy, and 147 patients in 2007 - 2011 
underwent a postoperative course of conformal chemoradiotherapy 
with temozolomide 75 mg/m2 an hour before radiation treatment 
during the first and the last 2 weeks of radiotherapy at the same 
doses. The patient survival was evaluated using the data of Belarusian 
Cancer Registry as of November 15, 2012 and calculated with Kaplan-
Meier method using the log-rank test and SPSS Statistics v.17 
software. 
Results: For the time being, 30 (55.6%) of 54 AA patients, 12 (70,6%) 
of 17 AO/AOD patients and 34 (17,9%) of 190 GBM patients are 
followed up. The median survival and 2-, 3- and 5-year survival rates 
for grade III gliomas are 33 months, 71.7±5.7%, 48.3±7.5% and 
39.1±8.5%; for grade IV GBM - 14 months, 22.6±3.2%, 11.2±2.7% and 
7.9±2.9% respectively (p<0.0001). The median survival of patients 
administered chemoradiotherapy for grade III glioma has not been 
attained yet, 3- and 5-year survival rates are 66.9±11.1%; the median 
survival of patients receiving radiotherapy is 29 months, and 3- and 5-
year survival rates are 36.8±8.9% and 27.6±8.8% respectively 
(p=0.034). For GBM treated with chemoradiotherapy, the median 
survival and 2-, 3- and 5-year survival rates are 16 months, 25.2±4.7%, 
11.1±3.9% and 7.4±4.0%; with radiotherapy - 12 months, 18.3±4.3%, 
9.8±3.3% and 8.4±3.1% respectively (p=0.035). The median survival for 
AO/AOD was higher then for AA and was 46 months and 29 months 
respectively (p=0.069). 
Conclusions: Postoperative conformal radio-(chemoradio) therapy at a 
TTD of 54-60 Gy provides 2-, 3- and 5-year survival rates of 71.7±5.7%, 
48.3±7.5%, 39.1±8.5% and 22.6±3.2%, 11.2±2.7%, 7.9±2.9% for grade III 
anaplastic glioma patients and grade IV GBM patients respectively, 
with median survival of 33 and 14 months respectively (p<0.0001). 
Postoperative conformal chemoradiotherapy improves treatment 
outcomes compared with radiotherapy for both anaplastic gliomas 
(p=0.034) and GBM (p=0.035).  
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Purpose/Objective: To review the safety and activity of radiotherapy 
with concurrent bevacizumab in recurrent malignant gliomas. Reasons 
to combine bevacizumab and RT include the ability of antiangionetic 
agents to senzitize tumor endothelium to RT by depletion of VEGF and 
reduction of its pro-survival signaling. Our retrospective analysis 
provides additional data out of a very limited number of studies about 
safety and feasibility of conventionel 3D-conformal re-irradiation in 
combination with bevacizumab as a salvage therapy for relapsed 
gliomas. 
Materials and Methods: Patients with recurrence of malignant gliomas 
who failed after standard treatment odf surgery, post operative 
radiotherapy ± Temozolomide received bevacizumab (10 mg/kg i.v.) 
every two weeks until tumor progression and hypofractionated (16 x 
2.66 Gy). The intervall between the two radiotherapy treatments was 
at least 4 months in our patients. The median physical doses of the 
first and second radiation course were 40-60 Gy and 39-60 Gy, 
respectively. The median cumulative biological equivalent doses (BED) 
were 215 Gy (α/β = 2 gy) and 100 Gy (α/β = 10 Gy): Median RT-volume 
was 143 cm³ and median cumulative RT-dose was 95 Gy.  
Results: 13 consecutive patients with reccurrent malignant gliomas (6 
GBM, 3 AAC, 3 LGG, 1 not applicable) received 2 cycles of 
bevacizumab prior to re-irradiation and underwent a repeat cranial 
MRI-scan for RT-planing. Patinets who respond or had SD proceed to 
radiation therapy in a 3D-conformal manner to 16 x 2.66 Gy: PTV 
inclosed the contrast-enhancing GTV, the surroundig oedema plus a 
additional margins of 2.5 cm. Critical structures like the optic chiasm 
were excluded and the dose to the re-irradiated target volume was 
restricted to a cumulative dose of 110 Gy. No Grade 3-4 acute toxicity 
developed, haematologic and non haematologic toxicities were 
transient. Until now 1 necrosis is seen in this cohort and all patients 
responded to therapy. The median PFS after re-irradiation is 4.9 
months, the median OS after re-irradiation is 8.2 months. 
Conclusions: 3D-conformal re-irradiation ± bevacizumab is save with a 
good quality of life for progressive HGG patients. The large re-
irradiation volumes were well tolerated with a low rate of one 
confirmed radiation necrosis in 13 patients. Pretreatment with 
radiochemotherapy (temozolomide) does not increase neurotoxicity. 
The PFS is comparable to more complex and less abundant high 
precission radiation techniques.  
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Purpose/Objective: Meningiomas comprise one third of the the 
primary brain tumor cases and occupy the second place (up to 20%) 
after gliomas concerning the extension among the tumors of the CNS. 
Surgical resection is regarded as choice method for meningioma 
treatment. However, in cases of complex localization and in case of 
placement near vital neurovascular structures, and also in case of 
partial resection or extended tumor growth, usage of stereotactic 
radiosurgery allows preventing of possible complications and reaching 
of radiosurgical control over the tumor. 
Materials and Methods: 63 patients with meningiomas underwent 
treatment at MC'Cyber Clinic of Spizhenko'. Acquired results of 42 
patients were analyzed. Among them 21 patient previously underwent 
surgery (1-3 operations), and 24 patients did not previously undergo 
surgery. Tumor volume was defined between 1.6 ml to 86.6 ml (on 
average 26.8ml). All the patients underwent course of stereotactic 
radiosurgery with the use of CyberKnife system for 1-5 fractions (on 
average 4.45) depending on the tumor volume. Radiation dose ranged 
from 1500 to 2800 cGy. All patients underwent standard assessments, 
as CT, MRI, and also magnetic-resonance imaging in regime of 
diffusion-weighed images (DWI) with definition of actual diffusion 
coefficient – ADC (Apparent Diffusion Coefficient). DWI and ADC 
implementation before and after radiosurgical treatment allowed not 
only qualitative, but also quantitative interpretation conducting of 
acquired results and objective assessment of tumor tissue reaction 
onto the radiation exposure  
Results: Radiological results assessment of radiosurgical treatment 
was conducted in 3, 6, 12 months. In majority of the cases there was 
clinical response evidenced. For the time of patients’ observation for 
3-30 months (on average 17.36 months) tumor volume decreased in 25 
patients (56.2%), 16 patients (35.6%) had the tumor unchanged 
(stabilization) and 1 patient (2.2%) had tumor growth. ADC coefficient 
increase was determined in all patients with tumor volume decrease 
and also in some patients with stable mass lesions’ sizes, and it 
significantly decreased in those patients who had extended 
meningioma growth. Thus, diffusion coefficient increase is evidenced 
in 27 (64.3%) of the patients. Hereinafter the conditions of those 
patients continued improving. At the same time, according to the 
literature data, without taking into account the ADC of MRI diffusion-
weighed images, decrease of tumor (meningioma) after radiosurgery 
was observed only in 18%, and stabilization of the process was seen in 
74% of the patients. ADC diffusion parameters in our patients with 
meningiomas before the start of treatment comprised 0.6-0.96 
mm2/s. After radiosurgical treatment diffusion coefficient equaled 
0.64-1.64 mm2/s. 
Conclusions: Stereotactic radiosurgery with the use of CyberKnife is 
effective treatment method for brain meningiomas. Objective 
assessment of treatment results is possible only by means of standard 
radiological methods (CT, MRI), supplemented with special MRI modes 
(DWI) and ADC determination. 
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Purpose/Objective: Radiation necrosis (RN) of the brain is an 
important problem for the patient with malignant astrocytoma, 
especially treated with high-dose RT. Individualized radiation dose 
delivery according to radiosensitivity may reduce the incidence of RN 
while keeping enough anti-tumor effect. And anti-tumor effect of 
irradiation was closely related to anti-tumor immune response of the 
host. The purpose of this study is to evaluate whether some 
parameters, which speculate the host's immune strength, could 
predicted the occurrence of RN at initial treatment. 
Materials and Methods: Between 2006 and 2010, 64 patients with 
malignant astrocytoma were enrolled. All patients were treated with 
RT and concurrent temozolomide (TMZ) followed by adjuvant TMZ. 
Thirty-three patients received conventional RT and the other 31 
received hypofractionated high-dose IMRT. In the IMRT group, three-
layered PTVs were contoured (PTV-1: enhanced lesion with 5mm 
margin, PTV-2: 15mm surrounding the PTV-1, PTV-3: FLAIR-high area) 
and different doses (68Gy for PTV-1, 40Gy for PTV2 and 32Gy for PTV-
3) were delivered by 8 fractions. To estimate the immune strength of 
the patients, we used tumor-infiltrating lymphocytes (CD4+ helper T 
cells, CD8+ cytotoxic Tcells and FoxP3+ regulatory T cells (Treg) which 
suppresses the cytotoxic effect of CD8+ T cells) at first surgery, 
cerebrospinal fluid cells and proteins a week after first surgery. After 
treatment, MRI was performed with an interval of one or two months. 
We estimated the prognostic effect of these immunobiological 
parameters on overall survival (OS), progression-free survival(PFS) and 
RN-free survival (RNFS). 
Results: High-dose hypofractionated IMRT induced RN more frequently 
than conventional RT (relative risk (RR) 3.44, p=0.0067) and tumor-
infiltrating CD8+ T cells was also independent risk factor of RN (RR 
3.10,p=0.0262). On the other hand, the infiltration of FoxP3+ Treg 
indicated lower risk of RN but not statistically significant. One-year 
RNFS for CD8 infiltration without FoxP3 and FoxP3 infiltration without 
CD8 were 50% and100%. Two-year RNFS were 0% and 86%, respectively 
(p=0.0013).Tumor-infiltrating lymphocytes was not related to OS and 
PFS in the entire analysis. In the subgroup analysis of IMRT, the 
infiltration of CD8+ cells was higher risk factor of RN (RR 3.88, 
p=0.0041). In the conventional RT group, the infiltration of CD8+ 




Conclusions: Tumor-infiltrating CD8+ T cells was the prognostic factor 
of RN after RT, especially high-dose RT, but was not related to OS. 
The analysis of tumor-infiltrating lymphocytes might be useful to 
prevent the occurrence of RN. 
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Purpose/Objective: To analyze the treatment outcomes and 
prognostic factors in patients with brain metastases (BM) from 
undiagnosed primary cancer (BM-UDP). 
Materials and Methods: Between January 2010 and October 2012, 
patients with brain metastases referred for palliative radiotherapy 
were enrolled for this study. BM-UDP patients underwent complete 
systemic survey for the origin of the cancer before the treatment 
began. All patients were treated with long-term palliative intent 
including whole brain radiotherapy (WBRT) and systemic therapies 
tailored for their primary origin. Patients were followed up until their 
death and overall survival (OS) were calculated from the day of BM 
diagnosis. Another group of patients with BM from diagnosed primary 
(BM-DP) who were treated in the same period of time were used for 
survival comparison. Potential prognosticators for OS in BM-UDP were 
analyzed. 
Results: Total 79 BM patients were treated and enrolled during this 
period, 37 were BM-UDP and 42 were BM-DP. There were no survival 
difference between BM-UDP and BM-DP patients compared by 
univariate analysis (p = 0.298). In BM-UDP patients, the median age 
was 61 years-old, 22 were male and 15 were female. The most 
common primary site was the lung (30/37). Median OS for these 
patients were 8.03 months. Multivariate analysis revealed that age, 
gender, extracranial metastases, number of BM lesions, and volume of 
the largest BM lesion were not prognosticators for OS. The only 
significant prognostic factor was performance status before WBRT. 
The median OS were 10.00 months and 2.89 months for patients with 
Karnofsky performance status (KPS) ≥ 70 and KPS < 70, respectively. 
(p = 0.006) 
